title: Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.
abstract: Although alterations of serotonin (5-HT) system functioning have been proposed for a variety of psychiatric disorders, a direct method quantitatively assessing 5-HT release capacity in the living human brain is still lacking. Therefore, we evaluated a novel method to assess 5-HT release capacity in vivo using dexfenfluramine challenge and [(18)F]altanserin positron emission tomography (PET). Thirteen healthy male subjects received placebo and single oral doses of 40 mg (n = 6) or 60 mg (n = 7) of the potent 5-HT releaser dexfenfluramine separated by an interval of 14 days. Three further subjects received placebo on both days. Two hours after placebo/drug administration, 250 MBq of the 5-HT(2A) receptor selective PET-radiotracer [(18)F]altanserin was administered intravenously as a 30s bolus. Dynamic PET data were subsequently acquired over 90 min. Moreover, arterial blood samples were drawn for measurement of total activity and metabolite correction of the input function. Dexfenfluramine as well as cortisol and prolactin plasma concentration-time profiles was quantitatively determined. Tracer distribution volumes for five volumes-of-interest (prefrontal and occipital cortex, insula, thalamus, caudatum) were calculated by the Logan plot and a 2-tissue compartment model. Dexfenfluramine dose-dependently decreased the total distribution volume of [(18)F]altanserin in cortical regions independent of the PET modeling approach. Cortisol and prolactin plasma concentrations were dose-dependently increased by dexfenfluramine. The decrease in cortical [(18)F]altanserin receptor binding under dexfenfluramine was correlated with the increase of plasma prolactin. These data suggest that the combination of a dexfenfluramine-induced 5-HT release and subsequent assessment of 5-HT(2A) receptor availability with [(18)F]altanserin PET is suitable to measure cortical 5-HT release capacity in the human brain.
authors: Clinic of Affective Disorders and General Psychiatry, University Hospital of Psychiatry, Zurich, Switzerland. quednow@bli.uzh.ch
authors: Boris B
authors: BB
authors: Quednow
authors: Valerie
authors: V
authors: Treyer
authors: Felix
authors: F
authors: Hasler
authors: Nadja
authors: N
authors: Dörig
authors: Matthias T
authors: MT
authors: Wyss
authors: Cyrill
authors: C
authors: Burger
authors: Katharina M
authors: KM
authors: Rentsch
authors: Gerrit
authors: G
authors: Westera
authors: Pius August
authors: PA
authors: Schubiger
authors: Alfred
authors: A
authors: Buck
authors: Franz X
authors: FX
authors: Vollenweider
mesh_terms: D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging* / Q000502:physiology*; D020372:Dexfenfluramine; D004311:Double-Blind Method; D005462:Fluorine Radioisotopes; D006801:Humans; D007650:Ketanserin / Q000031:analogs & derivatives*; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods; D012701:Serotonin / Q000378:metabolism*; D017366:Serotonin Receptor Agonists; D055815:Young Adult
chemical_list: D005462:Fluorine Radioisotopes; D017366:Serotonin Receptor Agonists; D012701:Serotonin; C071983:altanserin; D007650:Ketanserin; D020372:Dexfenfluramine